Skip to contentC
CV Sciences, Inc.
C
CVSICV Sciences, Inc. Q2 2021 · 10-Q
Revenue$5.13M$5.13M−5.0% vs Q2 2020 Net Income-$3.53M-$3.53MN/M vs Q2 2020 EPS Diluted-$0.03-$0.03N/M vs Q2 2020 Gross Profit$2,290,000−1.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CV Sciences, Inc. · CIK 1510964 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,064,000N/M Free Cash Flowderived-$3,064,000N/M Margins · derivedGross margin44.7%+1.6 pt vs Q2 2020
Operating margin-68.4%+17.9 pt vs Q2 2020
Net margin-68.8%+17.9 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 16, 2021 · 47 d after period end